The global pharma company with a research hub in Montreal is aiming to raise HK$2.03 billion, or about C$356 million, in an initial public offering. Insilico’s regulatory filing shows it had about US$212 million in cash on hand at mid-year, which would last 33 months at its current burn rate; the proceeds of the IPO would buy it an additional 42 months. Shares are due to start trading Dec. 30. (The Logic)

Talking point: Insilico founder Alex Zhavoronkov is a Latvian Canadian with a degree from Queen’s University and the firm’s Canadian operation was built around Concordia PhD Petrina Kamya, who is in charge of Insilico’s various AI development platforms. Insilico doesn’t have a drug on the market yet but has several in clinical trials; the farthest along is for treating pulmonary fibrosis. It also offers a set of drug-development tools for commercial use, and made a licensing deal with Eli Lilly in November that could be worth US$100 million.